var data={"title":"Penicillamine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Penicillamine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6741?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=penicillamine-drug-information\" class=\"drug drug_general\">see &quot;Penicillamine: Drug information&quot;</a> and <a href=\"topic.htm?path=penicillamine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Penicillamine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709199\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Physicians planning to use penicillamine should thoroughly familiarize themselves with its toxicity, special dosage considerations, and therapeutic benefits. Penicillamine should never be used casually. Each patient should remain constantly under the close supervision of the physician. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Toxicity symptoms:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Patients should be warned to report promptly any symptoms suggesting toxicity.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207480\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cuprimine;</li>\n      <li>Depen Titratabs</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207481\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cuprimine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060964\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Copper Toxicity</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antidote, Lead Toxicity</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Chelating Agent, Oral</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060958\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=penicillamine-drug-information\" class=\"drug drug_general\">see &quot;Penicillamine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Penicillamine administration increases requirement for pyridoxine. Patients may require a daily supplement of pyridoxine. A dose reduction (to 250 mg/day in adults) may be considered prior to surgical procedures. May resume normal recommended dosing postoperatively once wound healing is complete.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Wilson disease</b>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Diagnosis (adjunct): Penicillamine Challenge Test: Limited data available: Children &ge;2 years and Adolescents: Oral: 500 mg/dose for 2 doses; administer first immediately prior to a 24-hour urine collection and repeat 12 hours later. Urinary copper excretion &gt;1,600 mcg copper/24 hour (&gt;25 &micro;mol/24 hours) is consistent with Wilson disease (AASLD [Roberts 2008]; EASL 2012; Martins da Costa 1992; M&uuml;ller 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: Children and Adolescents: Oral: 20 mg/kg/day in 2 to 3 divided doses, round off to the nearest 250 mg dose; reduce dose by 25% when clinically stable; adult maximum daily dose: 1,500 mg/<b>day</b> (AASLD [Roberts 2008]; EASL 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystinuria: </b>Children and Adolescents: Oral: 20 to 40 mg/kg/day in 4 divided doses; maximum daily dose: 40 mg/kg/day (DeBerardinis 2008); adult maximum daily dose: 4,000 mg/day. Manufacturer recommends<b> i</b>f 4 equal doses are not possible, give the larger portion at bedtime and suggests dose should be adjusted to limit cysteine excretion to &lt;100 to 200 mg/day (&lt;100 mg/day with history of stone formation and/or pain). A retrospective chart review of 11 patients (age range: 1.2 to 12.5 years) with urolithiasis and high urinary cysteine receiving long-term penicillamine (~3 to 18 years) suggests that gradual initiation of penicillamine effectively lowers urinary cysteine concentrations and may limit toxicity associated with treatment. Therapy was initiated at 5 mg/kg/day and increased weekly by 5 mg/kg/day to a final dose of 20 mg/kg/day; five patients required further increases up to 40 mg/kg/day. Urinary cysteine concentrations decreased 5% to 81% while on treatment. Five patients did not reach the goal urinary cysteine concentration of &lt;1,200 micromolar. Six patients experienced acute stone crisis or had evidence of new stone formation on ultrasound; however, in all cases this was during periods of noncompliance to therapy (DeBerardinis 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lead poisoning:</b> <b>Note:</b> For the treatment of high blood lead levels in children, the CDC recommends chelation treatment when blood lead levels are &gt;45 mcg/dL (ACCLPP 2012; CDC 2002). AAP considers penicillamine a 3<sup>rd</sup> line agent for children when blood lead levels are &gt;45 mcg/dL and &lt;70 mcg/dL; children with blood lead levels &gt;70 mcg/dL or symptomatic lead poisoning should be treated with parenteral agents (AAP 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents: Limited data available, optimal dose not defined: Oral: Initial: 10 mg/kg/day divided twice daily for 2 weeks increase dose to 25 to 40 mg/kg/day (Kliegman 2016); increasing the dose over a few weeks has been suggested to improve tolerability (Shannon 1998). A reduced dosage of 15 mg/kg/day in 2 divided doses has been shown to be effective in the treatment of mild to moderate lead poisoning (blood lead concentration 20 to 40 mcg/dL) with a reduction in adverse effects (Shannon 2000); lower doses (10 to 15 mg/kg/day for 4 to 12 weeks) has also been suggested for treating lead concentrations of 45 to 69 mcg/dL (Chandran 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystinuria:</b> Oral: 1,000 to 4,000 mg/day in 4 divided doses; usual daily dose: 2,000 mg/day; initiation of therapy at 250 mg/day with gradual upward titration may reduce the risk of unwanted effects. <b>Note:</b> Adjust dose to limit cysteine excretion to 100 to 200 mg/day (&lt;100 mg/day with history of stone formation).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Wilson disease: </b>Oral: <b>Note:</b> Dose that results in an initial 24-hour urinary copper excretion &gt;2 mg/day should be continued for ~3 months; maintenance dose defined by amount resulting in &lt;10 mcg serum free copper/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer's labeling:</i> 750 to 1,500 mg/day in divided doses; maximum daily dose: 2,000 mg/<b>day</b>. <b>Note:</b> Limit daily dose to 750 mg/day in pregnant women; if planned cesarian, limit daily dose to 250 mg/day during the last 6 weeks of pregnancy and postoperatively until wound healing is complete.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternate recommendations:</i> To increase tolerability, therapy may be initiated at 250 to 500 mg/day then titrated upward in 250 mg increments every 4 to 7 days; usual maintenance dose: 750 to 1,000 mg/day in 2 divided doses; maximum: 1,000 to 1,500 mg/day in 2 to 4 divided doses (AASLD [Roberts 2008]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, the manufacturer&rsquo;s labeling suggests caution as the drug undergoes mainly renal elimination.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate recommendations: Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;50 mL/minute: No dosage adjustment needed (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;50 mL/minute: Avoid use (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Dialyzable. Administer 33% of usual dose (Aronoff 2007); a dosing decrease from 250 mg/day to 250 mg 3 times weekly after dialysis has been suggested in the treatment of rheumatoid arthritis (Swarup 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>There are no dosage adjustments provided in the manufacturer's labeling; however, only a small fraction is metabolized hepatically.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207453\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cuprimine: 250 mg [contains fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depen Titratabs: 250 mg [scored]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207438\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060969\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer on an empty stomach (1 hour before or 2 hours after meals) and at least 1 hour apart from other drugs, milk, antacids, and zinc or iron-containing products. Patients unable to swallow capsules may mix contents of capsule with fruit juice or chilled pureed fruit (Cuprimine prescribing information [Canada] 2012). Doses &le;500 mg may be administered as single dose; doses &gt;500 mg should be administered in divided doses.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Cystinuria: If administering 4 equal doses is not feasible, administer the larger dose at bedtime. Patients with cystinuria should drink copious amounts of water.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207474\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store in tight, well-closed containers.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060968\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of Wilson disease (FDA approved in pediatric patients [age not specified] and adults), treatment of cystinuria (FDA approved in pediatric patients [age not specified] and adults), adjunct treatment of severe active rheumatoid arthritis when conventional therapy has failed (FDA approved in adults); has also been used for diagnosis of Wilson disease and treatment of lead poisoning</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note: </b>Penicillamine is associated with significant toxicity, including glomerulonephritis (Nagahama 2002) and is not included in the rheumatoid arthritis guidelines from the American College of Rheumatology (Singh 2015). Due to toxicity associated with its use and the availability of alternative agents with less risk of toxicity, penicillamine should not be used for the treatment of rheumatoid arthritis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207532\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Penicillamine may be confused with penicillin </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depen [U.S.] may be confused with Depin brand name for nifedipine [India]; Depon brand name for acetaminophen [Greece]; Dipen brand name for diltiazem [Greece]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pemine [Italy] may be confused with Pamine brand name for methscopolamine [U.S., Canada]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207530\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Local thrombophlebitis, vasculitis (including renal vasculitis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, agitation, dystonia, Guillain-Barre syndrome, hyperpyrexia, myasthenia (including extraocular muscles), myasthenia gravis, neurological deterioration, neuropathy, psychiatric disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, cheilosis, exfoliative dermatitis, fragile skin (friability increased), lichen planus, papule (white papules at venipuncture and surgical sites), pemphigus, pruritus, skin atrophy (anetoderma), skin rash (early and late), toxic epidermal necrolysis, urticaria, wrinkling of skin (excessive), yellow nail syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypoglycemia, increased lactate dehydrogenase, thyroiditis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, diarrhea, dysgeusia, epigastric pain, glossitis, nausea, oral mucosa ulcer, pancreatitis, peptic ulcer (reactivation), stomatitis (gingivostomatitis), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Breast disease (mammary hyperplasia), Goodpasture's syndrome, hematuria, nephrotic syndrome, proteinuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, change in platelet count (increase), eosinophilia, hemolytic anemia, increased monocytes, leukocytosis, leukopenia, lymphadenopathy, positive ANA titer, pure red cell aplasia, sideroblastic anemia, thrombocytopenia, thrombotic thrombocytopenic purpura</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum alkaline phosphatase, hepatic failure, intrahepatic cholestasis, toxic hepatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, connective tissue disease (elastosis perforans serpiginosa), dermatomyositis, lupus-like syndrome, polyarthralgia (migratory, often with objective synovitis), polymyositis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blepharoptosis, diplopia, optic neuritis, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Asthma, bronchiolitis obliterans, hypersensitivity pneumonitis, interstitial pneumonitis, pulmonary fibrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous:  Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207461\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal insufficiency (in patients with rheumatoid arthritis); patients with previous penicillamine-related aplastic anemia or agranulocytosis; breast-feeding; pregnancy (in patients with rheumatoid arthritis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: Additional contraindications (not in US labeling):</i> Hypersensitivity to penicillamine or any component of the formulation; use in patients with chronic lead poisoning who have radiographic evidence of lead-containing substances in the GI tract; pregnancy (in patients with chronic lead poisoning); concomitant use with gold therapy, antimalarial or cytotoxic drugs, oxyphenbutazone or phenylbutazone</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207442\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Allergic reactions: Approximately 33% of patients will experience an allergic reaction. Rash may occur early (more commonly) or late in therapy; early-onset rash typically resolves within days of discontinuation of therapy and does not recur upon rechallenge with reduced dose; discontinue therapy for late-onset rash (eg, after &gt;6 months) and do not rechallenge; rash typically recurs with rechallenge. Discontinue therapy for skin reactions accompanied by lymphadenopathy, fever, arthralgia, or other allergic reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchiolitis obliterans: Has been reported rarely with use; instruct patients to report pulmonary symptoms (eg, unexplained wheezing or cough, exertional dyspnea) and consider pulmonary function testing in such patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic: Penicillamine increases the amount of soluble collagen; may increase skin friability, particularly at sites subject to pressure or trauma (eg, knees, elbows shoulders). Purpuric areas with localized bleeding (if skin is broken) or vesicles with dark blood may be observed. Effects are considered localized and do not necessitate discontinuation of therapy; may not recur with dose reduction. Macular cutaneous eruptions are sometimes observed in conjunction with drug fever, usually 2 -3 weeks after therapy initiation. Dose reduction may be considered prior to surgical procedures. May resume normal recommended dosing postoperatively once wound healing is complete.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug fever: Drug fever may be observed, usually 2-3 weeks after therapy initiation. Discontinue use in patients with rheumatoid arthritis, Wilson&rsquo;s disease, or cystinuria who develop a marked febrile response. Consider alternative therapy for patients with rheumatoid arthritis due to high incidence of fever reoccurrence with penicillamine rechallenge. May resume therapy at a reduced dose in Wilson&rsquo;s disease or cystinuria upon resolution of fever; dose should then be gradually titrated to effective dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal: Taste alteration may occur (rare in Wilson&rsquo;s disease); usually self-limited with continued therapy, however may last &ge;2 months and result in total loss of taste. Oral ulceration (eg, stomatitis) may occur; typically recurs on rechallenge but often resolves with dose reduction. Other dose-related lesions (eg, glossitis, gingivostomatitis) have been observed with use and may require therapy discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Goodpasture's syndrome: Penicillamine has been associated with fatalities due to Goodpasture's syndrome. Discontinue therapy immediately in patients with abnormal urinary findings in association with hemoptysis and pulmonary infiltrates on chest x-ray.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic toxicities: Penicillamine has been associated with fatalities due to agranulocytosis, aplastic anemia, and thrombocytopenia. Discontinue therapy for WBC &lt;3500/mm<sup>3</sup>. Withhold therapy at least temporarily for platelet counts &lt;100,000/mm<sup>3</sup> or a progressive fall in WBC or platelets in 3 successive determinations, even though values may remain within the normal range. Monitor for signs/symptoms of leukopenia and thrombocytopenia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Monitor liver function tests periodically due to rare reports of intrahepatic cholestasis or toxic hepatitis. More frequent monitoring is required during the first year of therapy in patients with Wilson&rsquo;s disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lupus erythematosus-like syndrome: May be observed in some patients; positive antinuclear antibody (ANA) test does not necessitate therapy discontinuation but should alert clinicians of possible future development of lupus erythematosus-like syndrome.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pemphigus: May occur early or late in therapy; discontinue use with suspicion of pemphigus. May treat with high-dose corticosteroids alone, or in conjunction with an immunosuppressant; treatment duration can range from weeks to &gt;1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Penicillin cross-sensitivity: Patients with a penicillin allergy may theoretically have cross-sensitivity to penicillamine; however, the possibility has been eliminated now that penicillamine is produced synthetically and no longer contains trace amounts of penicillin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Proteinuria/hematuria: Proteinuria or hematuria may develop; monitor for membranous glomerulopathy which can lead to nephrotic syndrome. In rheumatoid arthritis patients, discontinue if gross hematuria or persistent microscopic hematuria develop and discontinue therapy or reduce dose for proteinuria that is either &gt;1 g/day or progressively increasing. Dose reduction may lead to resolution of proteinuria.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Penicillamine has been associated with myasthenic syndrome, and in some cases, progression to myasthenia gravis. Resolution of symptoms has been observed in most cases following discontinuation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Toxicity symptoms: <b>[US Boxed Warning]: Patients should be warned to report promptly any symptoms suggesting toxicity (fever, sore throat, chills, bruising, or bleeding);</b> toxicity may be dose related.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cystinuria: Continue treatment on a daily basis; interruptions of even a few days have been followed by hypersensitivity with reinstitution of therapy. Patients should receive pyridoxine supplementation (25 mg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lead poisoning: Investigate, identify, and remove sources of lead exposure and confirm lead-containing substances are absent from the GI tract prior to initiating therapy. Do not permit patients to re-enter the contaminated environment until lead abatement has been completed. Penicillamine is considered to be a third-line agent for the treatment of lead poisoning in children due to the overall toxicity associated with its use (AAP, 2005; Chandran, 2010); penicillamine should only be used when unacceptable reactions have occurred with edetate CALCIUM disodium and succimer. Primary care providers should consult experts in the chemotherapy of lead toxicity before using chelation drug therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rheumatoid arthritis: Patients with rheumatoid arthritis and impaired nutrition should receive pyridoxine supplementation (25 mg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Wilson's disease: Continue treatment on a daily basis; interruptions of even a few days have been followed by hypersensitivity with reinstitution of therapy. Worsening of neurologic symptoms may occur during initiation of therapy however discontinuation of therapy is not recommended; may consider concomitant use of short term dimercaprol in patients whose symptoms continue to worsen 1 month following therapy initiation. Patients should receive pyridoxine supplementation (25-50 mg/day; Roberts, 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematopoietic-depressant drugs: Use with caution in patients on other hematopoietic-depressant drugs (eg, gold, immunosuppressants, antimalarials, phenylbutazone; Canadian labeling contraindicates concomitant use with these agents); hematologic and renal adverse reactions are similar.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; may be more susceptible to skin rash and/or taste alterations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should be administered under the close supervision of a physician familiar with the toxicity and dosage considerations. </b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299837\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207447\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12685&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of PenicillAMINE.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: PenicillAMINE may decrease the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: May decrease the absorption of PenicillAMINE. Only oral iron salts are a concern.<b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of PenicillAMINE. Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction; however, the success of this action is unproven.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Polaprezinc: May decrease the serum concentration of PenicillAMINE.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207475\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Penicillamine serum levels may be decreased if taken with food. Management: Administer on an empty stomach 1 hour before or 2 hours after meals and at least 1 hour apart from other drugs, milk, antacids, and zinc- or iron-containing products. Certain disease states require further diet adjustment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207449\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207464\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Birth defects, including congenital cutix laxa and associated defects, have been reported in infants following penicillamine exposure during pregnancy. Use for the treatment of rheumatoid arthritis during pregnancy is contraindicated. Use for the treatment of cystinuria only if the possible benefits to the mother outweigh the potential risks to the fetus. Continued treatment of Wilson's disease during pregnancy protects the mother against relapse. Discontinuation has detrimental maternal and fetal effects. Daily dosage should be limited to 750 mg. For planned cesarean section, reduce dose to 250 mg/day for the last 6 weeks of pregnancy, and continue at this dosage until wound healing is complete.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060963\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Urinalysis, CBC with differential, platelet count, skin, lymph nodes, and body temperature twice weekly during the first month of therapy, then every 2 weeks for 5 months, then monthly. Monitor urinalysis for proteinuria and hematuria; if proteinuria develops a quantitative 24-hour urine protein at 1- to 2-week intervals initially (first 2 to 3 months) is recommended. LFTs every 6 months; signs/symptoms of hypersensitivity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cystinuria: 24-hour urinary cysteine (baseline and then every 6 to 12 months), annual X-ray for renal stones; some have recommended renal ultrasound every 6 months to monitor for efficacy and copper and zinc concentrations to monitor toxicity (DeBerardinis 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lead poisoning: Serum lead concentration (baseline and 7 to 21 days after completing chelation therapy) (CDC 2002); hemoglobin or hematocrit, iron status, free erythrocyte protoporphyrin or zinc protoporphyrin; neurodevelopmental changes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Wilson disease: Serum nonceruloplasmin-bound copper, 24-hour urinary copper excretion, LFTs every 3 months during the first year of treatment; periodic ophthalmic exam. Copper excretion is highest initially after treatment and may exceed 1,000 mcg/day; chronic treatment should produce urinary copper excretion of 200 to 500 mcg/day on treatment; values &lt;200 mcg/day may be due to either noncompliance or overtreatment which may be differentiated by measuring nonceruloplamin-bound copper (high in noncompliance and low in overtreatment) (AASLD [Roberts 2008]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060967\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Wilson disease: Adequate treatment: Serum nonceruloplasmin-bound copper &lt;15 mcg/dL (Serum nonceruloplasmin bound copper = Total copper - ceruloplasmin copper); 24-hour urinary copper excretion 200 to 500 mcg (3 to 8 micromoles)/day (AASLD [Roberts 2008])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207441\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Chelates with lead, copper, mercury and other heavy metals to form stable, soluble complexes that are excreted in urine; depresses circulating IgM rheumatoid factor, depresses T-cell but not B-cell activity; combines with cystine to form a compound which is more soluble, thus cystine calculi are prevented</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207460\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Rheumatoid arthritis: 2 to 3 months; Wilson disease: 1 to 3 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid but incomplete (40% to 70%); reduced by food, antacids, and iron</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &gt;80% to albumin and ceruloplasmin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic (small amounts metabolized to s-methyl-d-penicillamine)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 1.7 to 7 hours (Roberts 2008); large variations exist and a slow elimination phase lasting 4 to 6 days may occur after prolonged treatment has been stopped.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 1 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (primarily as disulfides)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207459\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 50 mg/mL oral suspension may be made with capsules. Mix the contents of sixty 250 mg capsules with 3 g carboxymethylcellulose, 150 g sucrose, 300 mg citric acid, and parabens (methylparaben 120 mg, propylparaben 12 mg). Add quantity of propylene glycol sufficient to make 100 mL, then add quantity of purified water sufficient to make 300 mL. Cherry flavor may be added. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Stable for 30 days refrigerated.</p>\n    <div class=\"reference\">DeCastro FJ, Jaeger RQ, and Rolfe UT, &quot;An Extemporaneously Prepared Penicillamine Suspension Used to Treat Lead Intoxication,&quot; <i>Hosp Pharm</i>, 1977, 2:446-8.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207463\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Cuprimine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $31,426.37</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Depen Titratabs Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $7,270.19</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207466\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adalken (MX);</li>\n      <li>Artamin (AE, AT, CY, JO, KR, KW, LK, MY, PL, QA, SA);</li>\n      <li>Artamine (EG);</li>\n      <li>Atamir (DK);</li>\n      <li>Byanodine (HU);</li>\n      <li>Cilamin (IN);</li>\n      <li>Cuprenil (BG, HN, PL);</li>\n      <li>Cuprimine (BB, MY, NL, NO, TH, TW);</li>\n      <li>Cuprimune (AR, BR);</li>\n      <li>Cupripen (AR, CU, ES);</li>\n      <li>D-Penamine (AU, NZ);</li>\n      <li>D-Penil (PE);</li>\n      <li>Distamine (GB, MT, NL);</li>\n      <li>Kelatin (BE, LU, NL);</li>\n      <li>Kelatine (PT);</li>\n      <li>Kuprenil (UA);</li>\n      <li>Mercaptyl (CH);</li>\n      <li>Metalcaptase (DE, HR, JP, LU, TW);</li>\n      <li>Metalcaptase[inj.] (CZ, HR);</li>\n      <li>Pemine (IT);</li>\n      <li>Penamine (JO);</li>\n      <li>Penicilamin (CZ);</li>\n      <li>Penicillamin (FI, SE);</li>\n      <li>Reumacillin (FI);</li>\n      <li>Trisorcin (HR);</li>\n      <li>Trolovol (FR, HR);</li>\n      <li>Vistamin (PK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Advisory Committee on Childhood Lead Poisoning Prevention (ACCLPP). Low-level lead exposure harms children: A renewed call for primary intervention. January 4, 2012. Available at <a href=\"http://www.cdc.gov/nceh/lead/acclpp/final_document_030712.pdf%20\" target=\"_blank\">http://www.cdc.gov/nceh/lead/acclpp/final_document_030712.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Environmental Health, &ldquo;Lead Exposure in Children: Prevention, Detection, and Management,&rdquo; <i>Pediatrics</i>, 2005, 116(4):1036-46.\\<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillamine-pediatric-drug-information/abstract-text/16199720/pubmed\" target=\"_blank\" id=\"16199720\">16199720</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). <i>Managing Elevated Blood Lead Levels Among Young Children: Recommendations from the Advisory Committee on Childhood Lead Poisoning Prevention</i>, Atlanta: CDC; 2002.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillamine-pediatric-drug-information/abstract-text/16199720/pubmed\" target=\"_blank\" id=\"16199720\">16199720</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chandran L and Cataldo R, &ldquo;Lead Poisoning: Basics and New Developments,&rdquo; <i>Pediatr Rev</i>, 2010, 31(10):399-406.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillamine-pediatric-drug-information/abstract-text/20889734/pubmed\" target=\"_blank\" id=\"20889734\">20889734</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cuprimine (penicillamine) [prescribing information]. Hunty Valley, MD: Aton Pharma; November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cuprimine (penicillamine) [Canada prescribing information]. Laval, Quebec: Valeant Canada LP; February 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DeBerardinis RJ, Coughlin CR 2nd, Kaplan P. Penicillamine therapy for pediatric cystinuria: experience from a cohort of American children. <i>J Urol</i>. 2008;180(6):2620-2623.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillamine-pediatric-drug-information/abstract-text/18951580/pubmed\" target=\"_blank\" id=\"18951580\">18951580</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson's disease. <i>J Hepatol</i>. 2012;56(3):671-685.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillamine-pediatric-drug-information/abstract-text/22340672/pubmed\" target=\"_blank\" id=\"22340672\">22340672</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martins da Costa C, Baldwin D, Portmann B, Lolin Y, Mowat AP, Mieli-Vergani G. Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease. <i>Hepatology</i>. 1992;15(4):609-615.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillamine-pediatric-drug-information/abstract-text/1551638/pubmed\" target=\"_blank\" id=\"1551638\">1551638</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    M&uuml;ller T, Koppikar S, Taylor RM, et al. Re-evaluation of the penicillamine challenge test in the diagnosis of Wilson's disease in children. <i>J Hepatol</i>. 2007;47(2):270-276.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillamine-pediatric-drug-information/abstract-text/17449133/pubmed\" target=\"_blank\" id=\"17449133\">17449133</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nagahama K, Matsushita H, Hara M, Ubara Y, Hara S, Yamada A. Bucillamine induces membranous glomerulonephritis. <i>Am J Kidney Dis</i>. 2002;39(4):706-712.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillamine-pediatric-drug-information/abstract-text/11920335/pubmed\" target=\"_blank\" id=\"11920335\">11920335</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roberts EA, Schilsky ML, and American Association for Study of Liver Diseases (AASLD),&quot; Diagnosis and Treatment of Wilson Disease: An Update,&quot; <i>Hepatology</i>, 2008, 47(6):2089-111.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillamine-pediatric-drug-information/abstract-text/18506894/pubmed\" target=\"_blank\" id=\"18506894\">18506894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shannon MW and Townsend MK, &ldquo;Adverse Effects of Reduced-Dose d-Penicillamine in Children With Mild-to-Moderate Lead Poisoning,&rdquo; <i>Ann Pharmacother</i>, 2000, 34(1):15-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillamine-pediatric-drug-information/abstract-text/10669180/pubmed\" target=\"_blank\" id=\"10669180\">10669180</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2016;68(1):1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillamine-pediatric-drug-information/abstract-text/26545825/pubmed\" target=\"_blank\" id=\"26545825\">26545825</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Swarup A, Sachdeva N, Schumacher HR Jr. Dosing of antirheumatic drugs in renal disease and dialysis. <i>J Clin Rheumatol</i>. 2004;10(4):190-204.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillamine-pediatric-drug-information/abstract-text/17043508/pubmed\" target=\"_blank\" id=\"17043508\">17043508</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12685 Version 78.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709199\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F207480\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F207481\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1060964\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1060958\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F207453\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F207438\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1060969\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F207474\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1060968\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F207532\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F207530\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F207461\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F207442\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299837\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F207447\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F207475\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F207449\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F207464\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1060963\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1060967\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F207441\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F207460\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F207459\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F207463\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F207466\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12685|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=penicillamine-drug-information\" class=\"drug drug_general\">Penicillamine: Drug information</a></li><li><a href=\"topic.htm?path=penicillamine-patient-drug-information\" class=\"drug drug_patient\">Penicillamine: Patient drug information</a></li></ul></div></div>","javascript":null}